Protecting Medicaid for People with Lung Cancer“When Wynn first went to the hospital for a collapsed lung, she didn’t have health insurance and believed that she did not get the care she needed. Doctors did an x-ray and dealt with the immediate problem, but did not...
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer “TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq:...
J&J says its lung cancer drug combination keeps people alive longer“Key Points: Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca’s Tagrisso in a clinical trial....
Diabetes drug appears to fight lung cancer — but only in overweight or obese patients“Research conducted at Roswell Park Comprehensive Cancer Center has revealed that metformin also appears to fight lung cancer — but only in overweight or obese patients. Further,...
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC“Key Takeaways: Pembrolizumab plus chemotherapy significantly improved 4-year OS and EFS in resectable early-stage NSCLC compared to chemotherapy alone. The pembrolizumab regimen showed a...
FDA Grants Taletrectinib Priority Review for Advanced ROS1+ NSCLC“The FDA has granted priority review to a new drug application for taletrectinib, an investigational next-generation ROS1 TKI, for the treatment of patients with advanced ROS1-positive non–small cell...
More News and Updates